Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States

Journal of Medical Economics

Volumn 19, Issue 12, 2016, Pages 1175-1186

  Cai, Jennifer ^a   Wang, Yuexi ^b   Baser, Onur ^b,c   Xie, Lin ^b   Chow, Wing ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b STATINMED RESEARCH   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

Adherence; Anti hyperglycemic; Diabetes; DPP 4; GLP 1; Persistence; SGLT2

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EXENDIN 4; LINAGLIPTIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DIABETIC PATIENT; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACY; RETROSPECTIVE STUDY; UNITED STATES; DIABETES MELLITUS, TYPE 2; ECONOMICS; MEDICATION COMPLIANCE;

DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MEDICATION ADHERENCE; PEPTIDES; RETROSPECTIVE STUDIES; UNITED STATES; VENOMS;

EID: 84978161601     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2016.1208208     Document Type: Article

References (38)

1. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence:terminology and definitions. Value Health 2008;11:44-7
2. Feldman BS, Cohen-Stavi CJ, Leibowitz M, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLoS One 2014;9:e108145
3. Iglay K, Cartier SE, Rosen VM, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin 2015;31:1283-96
4. Couto JE, Panchal JM, Lal LS, et al. Geographic variation in medication adherence in commercial and Medicare part D populations. J Manag Care Spec Pharm 2014;20:834-42
5. Manteuffel M, Williams S, Chen W, et al. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014;23:112-19
6. Tan E, Yang W, Pang B, et al. Geographic variation in antidiabetic agent adherence and glycemic control among patients with type 2 diabetes. J Manag Care Spec Pharm 2015;21:1195-202
7. Guillausseau PJ., Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29:79-81
8. Ho PM, Magid DJ, Masoudi FA, et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006;6:48
9. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012;35:1279-84
10. McAdam-Marx C, Bellows BK, Unni S, et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes:cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm 2014;20:691-700
11. Ayyagari R, Wei W, Cheng D, et al. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health 2015;18:198-205
12. Buysman EK, Liu F, Hammer M, et al. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide:a retrospective cohort study. Adv Ther 2015;32:341-55
13. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
14. Institute for Healthcare Improvement (IHI). The IHI Triple Aim. http://www.ihi.org/engage/initiatives/tripleaim/Pages/default.aspx. Accessed February 16, 2016
15. Berwick DM, Nolan TW, Whittington J., The triple aim:care, health, and cost. Health Aff (Millwood) 2008;27:759-69
16. Seabury SA, Lakdawalla DN, Dougherty JS, et al. Medication adherence and measures of health plan quality. Am J Manag Care 2015;21:e379-89
17. National Quality Forum. Adherence to Oral Diabetes Agents for Individuals with Diabetes Mellitus (NQF#2468). http://www.qualityforum.org/. Accessed January 29, 2016
18. Pharmacy Quality Alliance. Executive update on medication quality measures in Medicare part D plan ratings 2013. 2015. http://pqaalliance.org/measures/cms.asp. Accessed January 29, 2016
19. American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care 2016;39(Suppl 1):S52-S9
20. Farr AM, Sheehan JJ, Curkendall SM, et al. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287-305
21. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 2014;31:1119-33
22. Malmenas M, Bouchard JR, Langer J., Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 mug. Clin Ther 2013;35:795-807
23. Pelletier EM, Pawaskar M, Smith PJ, et al. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States:results from a retrospective claims database analysis. J Med Econ 2012;15:1039-50
24. Yu M, Xie J, Fernandez Lando L, et al. Liraglutide versus exenatide once weekly:Persistence, adherence, and early discontinuation. Clin Ther 2016;38:149-60
25. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600
26. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin:a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64
27. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week randomized trial. Diabetes Care 2013;36:2508-15
28. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy:a randomised trial. Diabetologia 2013;56:2582-92
29. Thayer S, Chow W, Korrer S, et al. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087–96
30. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus:Systematic review and network meta-analysis. Diabetes Obes Metab 2016. doi:10.1111/dom.12670
31. Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-40
32. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
33. Von Korff M, Wagner EH, Saunders K., A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
34. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
35. Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013;51:S11-S21
36. Pharmacy Quality Alliance. PQA medication quality measures in the health insurance marketplace:Quality rating system (QRS) beta test measure set. http://pqaalliance.org/measures/qrs.asp. Accessed January 27, 2016
37. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes:the ENTRED study 2007, a French Population-Based Study. PLoS One 2012;7:e32412
38. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin:results of a randomized, double-blind, crossover study. Diabetes Obes Metab 2015;17:188-97